Mazdutide
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
Innovent · Phase 1/2 · Completed · Enrollment 60
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| IBI362 | Obesity or overweight | n/r | n/r | n/r | n/r |
| placebo | Obesity or overweight | n/r | n/r | n/r | n/r |